Chairman of Zydus Lifesciences, Pankaj Patel, on Sunday expressed his gratitude upon being bestowed with the Padma Bhushan ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Zydus Lifesciences Chairman Pankaj R Patel has been awarded the prestigious Padma Bhushan for his contributions to the ...

Chairman of Zydus Lifesciences, Pankaj Patel, on Sunday thanked the Government for bestowing Padma Bhushan upon him, and said he was “extremely grateful for the recognition”. Pankaj Ramanbhai Patel, ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary.

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

The Ahmedabad -based Patel, whose Zydus Group runs a chain of multi-specialty hospitals, further said, “We are taking a leap ...